# US 2018/0021406 A1 · Pharmaceutical removal of vascular and/or neuronal extensions from a degenerating disc

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021406 A1
- Document ID: US20180021406A1
- Status: Published application
- Kind: A1
- Application number: 15/720,907
- Filed: 2017-09-29
- Published: 2018-01-25
- Earliest claimed: 2006-04-28
- Assignees: Warsaw Orthopedic, Inc.
- Applicants: Warsaw Orthopedic, Inc.
- Inventors: Josee Roy; Susan J. Drapeau; Jeffrey C. Marx
- Web page: https://patentgrep.com/patent/US20180021406A1

## CPC

- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/2093: {Leukaemia inhibitory factor [LIF]}
- A61K 38/212: {IFN-alpha}
- A61K 31/225: Polycarboxylic acids
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 2039/505: {comprising antibodies}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C07K 14/48: Nerve growth factor [NGF]
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.

## Claims

### Claim 1

A method for treating back or neck pain with or without radiculopathy comprising providing an effective amount of a therapeutic agent comprising ReN-1820, ALE-0540 and capsaicin to a disc region comprising a disc, the therapeutic agent adapted to disrupt a neuronal element in the disc region and a vascular element in the disc region.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disc is a degenerated disc.

### Claim 3 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to destroy, force retraction or block further growth of the neuronal element or vascular element in the disc region.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 3)

The method of claim 3, wherein the therapeutic agent modulates at least one extra-cellular matrix component, or modulates the response of the neuronal element or the vascular element to the at least one extra-cellular matrix component.

### Claim 7 (depends on 6)

The method of claim 6, wherein the extra-cellular matrix component is selected from a set consisting of chondroitin sulfate proteglycans, netrins, semaphorins, myelin/oligodendrocyte growth inhibitors and cell adhesion molecules.

### Claim 8 (depends on 7)

The method of claim 7 wherein the cell adhesion molecule is selected from a set consisting of NCAM, N-cadherins, cadherins and integrins.

### Claim 9 (depends on 3)

The method of claim 3, wherein the therapeutic agent modulates a cytoskeletal component of the neuronal element or the vascular element.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cytoskeletal component is selected from a set consisting of actins, tubulins, neurofilaments and microtubules.

### Claim 11 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to desensitize the neuronal element innervating the disc region.

### Claim 12 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to modulate a receptor or a molecule that binds to a receptor of the neuronal element innervating the disc region.

### Claim 13 (depends on 12)

The method of claim 12, wherein the therapeutic agent is adapted to modulate neuronal receptors selected from a set consisting of nociceptors, vanilloid, adrenergic, cholinergic, glutamate, GABA, serotonine, somatostatin opioids, ATP, Na+, K+, Ca2+, cannabinoids, Substance P and neuropeptide receptors.

### Claim 14 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to block the modulation of neuronal or vascular elements by a pro-inflammatory molecule.

### Claim 15 (depends on 14)

The method of claim 14, wherein the pro-inflammatory molecule is selected from a set consisting of cytokines, chemokines, neuropeptides, bradykinin, histamine and prostaglandins.

### Claim 16 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to modulate glial cells.

### Claim 17 (depends on 16)

The method of claim 16, wherein the therapeutic agent is toxic to the glial cells.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the ReN-1820, ALE-0540 and capsaicin are encapsulated in a depot comprising microbubbles comprising a protective coating and having a polymer comprising polyaspirins or poly(N-isopropylacrylamide) that provides for timed local release.

### Claim 20 (depends on 19)

The method of claim 19 further comprising subjecting the microbubbles to sonic energy to release the ReN-1820, ALE-0540 and capsaicin to at least an annulus fibrosus region or a nucleus pulposus region of a disc.
